

Sean M Hays

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1068971/publications.pdf>

Version: 2024-02-01

63
papers

2,505
citations

159525

30
h-index

197736

49
g-index

63
all docs

63
docs citations

63
times ranked

2348
citing authors

#	ARTICLE	IF	CITATIONS
1	Human biomonitoring assessment values: Approaches and data requirements. <i>International Journal of Hygiene and Environmental Health</i> , 2011, 214, 348-360.	2.1	156
2	Guidelines for the derivation of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. <i>Regulatory Toxicology and Pharmacology</i> , 2008, 51, S4-S15.	1.3	147
3	Sources of Variability in Biomarker Concentrations. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2014, 17, 45-61.	2.9	133
4	Evaluation of Biomonitoring Data from the CDC National Exposure Report in a Risk Assessment Context: Perspectives across Chemicals. <i>Environmental Health Perspectives</i> , 2013, 121, 287-294.	2.8	126
5	A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. <i>Journal of Applied Toxicology</i> , 2014, 34, 525-536.	1.4	123
6	Guidelines for the communication of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. <i>Regulatory Toxicology and Pharmacology</i> , 2008, 51, S16-S26.	1.3	99
7	Variation in Urinary Flow Rates According to Demographic Characteristics and Body Mass Index in NHANES: Potential Confounding of Associations between Health Outcomes and Urinary Biomarker Concentrations. <i>Environmental Health Perspectives</i> , 2015, 123, 293-300.	2.8	89
8	Biomonitoring Equivalents (BE) dossier for cadmium (Cd) (CAS No. 7440-43-9). <i>Regulatory Toxicology and Pharmacology</i> , 2008, 51, S49-S56.	1.3	82
9	Using Biomonitoring Equivalents to interpret human biomonitoring data in a public health risk context. <i>Journal of Applied Toxicology</i> , 2009, 29, 275-288.	1.4	81
10	Interpreting variability in population biomonitoring data: Role of elimination kinetics. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2012, 22, 398-408.	1.8	78
11	Biomonitoring Equivalents for inorganic arsenic. <i>Regulatory Toxicology and Pharmacology</i> , 2010, 58, 1-9.	1.3	71
12	Biomonitoring Equivalents for bisphenol A (BPA). <i>Regulatory Toxicology and Pharmacology</i> , 2010, 58, 18-24.	1.3	65
13	Biomonitoring Equivalents for selenium. <i>Regulatory Toxicology and Pharmacology</i> , 2014, 70, 333-339.	1.3	65
14	Derivation of Biomonitoring Equivalents for di-n-butyl phthalate (DBP), benzylbutyl phthalate (BzBP), and diethyl phthalate (DEP). <i>Regulatory Toxicology and Pharmacology</i> , 2009, 55, 259-267.	1.3	56
15	Biomonitoring Equivalents (BE) dossier for 2,4-dichlorophenoxyacetic acid (2,4-D) (CAS No. 94-75-7). <i>Regulatory Toxicology and Pharmacology</i> , 2008, 51, S37-S48.	1.3	51
16	Human biomonitoring as a pragmatic tool to support health risk management of chemicals – Examples under the EU REACH programme. <i>Regulatory Toxicology and Pharmacology</i> , 2011, 59, 125-132.	1.3	49
17	Biomonitoring Equivalents for DDT/DDE. <i>Regulatory Toxicology and Pharmacology</i> , 2011, 60, 172-180.	1.3	47
18	Evaluation of urinary speciated arsenic in NHANES: Issues in interpretation in the context of potential inorganic arsenic exposure. <i>Regulatory Toxicology and Pharmacology</i> , 2014, 69, 49-54.	1.3	47

#	ARTICLE	IF	CITATIONS
19	Screening of population level biomonitoring data from the Canadian Health Measures Survey in a risk-based context. <i>Toxicology Letters</i> , 2014, 231, 126-134.	0.4	43
20	Biomonitoring Equivalents for molybdenum. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 77, 223-229.	1.3	40
21	Derivation of Biomonitoring Equivalents for di(2-ethylhexyl)phthalate (CAS No. 117-81-7). <i>Regulatory Toxicology and Pharmacology</i> , 2009, 55, 249-258.	1.3	38
22	Perspective on serum dioxin levels in the United States: an evaluation of the NHANES data. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2009, 19, 435-441.	1.8	37
23	Biomonitoring Equivalents for di-isononyl phthalate (DINP). <i>Regulatory Toxicology and Pharmacology</i> , 2011, 60, 181-188.	1.3	37
24	Interpreting human biomonitoring data in a public health risk context using Biomonitoring Equivalents. <i>International Journal of Hygiene and Environmental Health</i> , 2012, 215, 145-148.	2.1	37
25	Biomonitoring Equivalents (BE) dossier for acrylamide (AA) (CAS No. 79-06-1). <i>Regulatory Toxicology and Pharmacology</i> , 2008, 51, S57-S67.	1.3	36
26	Biomonitoring Data for 2,4-Dichlorophenoxyacetic Acid in the United States and Canada: Interpretation in a Public Health Risk Assessment Context Using Biomonitoring Equivalents. <i>Environmental Health Perspectives</i> , 2010, 118, 177-181.	2.8	36
27	Biomonitoring Equivalents for triclosan. <i>Regulatory Toxicology and Pharmacology</i> , 2010, 58, 10-17.	1.3	35
28	Biomonitoring Equivalents for deltamethrin. <i>Regulatory Toxicology and Pharmacology</i> , 2011, 60, 189-199.	1.3	35
29	Public health interpretation of trihalomethane blood levels in the United States: NHANES 1999-2004. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2010, 20, 255-262.	1.8	34
30	Hexavalent chromium reduction kinetics in rodent stomach contents. <i>Chemosphere</i> , 2012, 89, 487-493.	4.2	34
31	Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs) - Application of steady-state PBPK model solutions. <i>Regulatory Toxicology and Pharmacology</i> , 2010, 58, 33-44.	1.3	30
32	Biomonitoring-based risk assessment for hexabromocyclododecane (HBCD). <i>International Journal of Hygiene and Environmental Health</i> , 2011, 214, 179-187.	2.1	30
33	Biomonitoring Equivalents for benzene. <i>Regulatory Toxicology and Pharmacology</i> , 2012, 62, 62-73.	1.3	30
34	Screening-level Biomonitoring Equivalents for tiered interpretation of urinary 3-phenoxybenzoic acid (3-PBA) in a risk assessment context. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 92, 29-38.	1.3	29
35	Biomonitoring equivalents for hexachlorobenzene. <i>Regulatory Toxicology and Pharmacology</i> , 2010, 58, 25-32.	1.3	27
36	Biomonitoring Equivalents (BE) dossier for toluene (CAS No. 108-88-3). <i>Regulatory Toxicology and Pharmacology</i> , 2008, 51, S27-S36.	1.3	26

#	ARTICLE	IF	CITATIONS
37	Derivation of Biomonitoring Equivalents for cyfluthrin. <i>Regulatory Toxicology and Pharmacology</i> , 2009, 55, 268-275.	1.3	25
38	Derivation of Biomonitoring Equivalent (BE) Values for 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (TCDD) and Related Compounds: A Screening Tool for Interpretation of Biomonitoring Data in a Risk Assessment Context. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2008, 71, 1499-1508.	1.1	20
39	Biomonitoring Equivalents for 2,2,4,4,5-pentabromodiphenylether (PBDE-99). <i>Regulatory Toxicology and Pharmacology</i> , 2011, 60, 165-171.	1.3	20
40	2,4-D Exposure and risk assessment: Comparison of external dose and biomonitoring based approaches. <i>Regulatory Toxicology and Pharmacology</i> , 2012, 64, 481-489.	1.3	20
41	The role of human biological monitoring in health risk assessment. <i>International Journal of Risk Assessment and Management</i> , 2017, 20, 136.	0.2	20
42	Consideration of dosimetry in evaluation of <i>ToxCast</i> data. <i>Journal of Applied Toxicology</i> , 2011, 31, 741-751.	1.4	19
43	Evaluation of NHANES biomonitoring data for volatile organic chemicals in blood: Application of chemical-specific screening criteria. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2012, 22, 24-34.	1.8	19
44	Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin of exposure values for hexavalent chromium. <i>Journal of Applied Toxicology</i> , 2018, 38, 351-365.	1.4	19
45	Biomonitoring Equivalents (BE) dossier for trihalomethanes. <i>Regulatory Toxicology and Pharmacology</i> , 2008, 51, S68-S77.	1.3	18
46	Implementing a framework for integrating toxicokinetics into human health risk assessment for agrochemicals. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 75, 89-104.	1.3	18
47	Derivation of human Biomonitoring Guidance Values for chlorpyrifos using a physiologically based pharmacokinetic and pharmacodynamic model of cholinesterase inhibition. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 71, 235-243.	1.3	16
48	Reduction of hexavalent chromium by fasted and fed human gastric fluid. II. Ex vivo gastric reduction modeling. <i>Toxicology and Applied Pharmacology</i> , 2016, 306, 120-133.	1.3	16
49	California biomonitoring data: Comparison to NHANES and interpretation in a risk assessment context. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 73, 875-884.	1.3	12
50	Biomonitoring Equivalents for interpretation of urinary iodine. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 94, 40-46.	1.3	12
51	Development of Screening Tools for the Interpretation of Chemical Biomonitoring Data. <i>Journal of Toxicology</i> , 2012, 2012, 1-10.	1.4	11
52	Biomonitoring Equivalents (BEs) for tetrabromobisphenol A. <i>Regulatory Toxicology and Pharmacology</i> , 2019, 102, 108-114.	1.3	10
53	Assessment of margin of exposure based on biomarkers in blood: An exploratory analysis. <i>Regulatory Toxicology and Pharmacology</i> , 2011, 61, 44-52.	1.3	9
54	Application of human biomonitoring (HBM) of chemical exposure in the characterisation of health risks under REACH. <i>International Journal of Hygiene and Environmental Health</i> , 2012, 215, 238-241.	2.1	9

#	ARTICLE	IF	CITATIONS
55	Risk assessment for children exposed to decabromodiphenyl (oxide) ether (deca) in the United States. Integrated Environmental Assessment and Management, 2006, 2, 2-12.	1.6	6
56	Interpreting Estrogen Screening Assays in the Context of Potency and Human Exposure Relative to Natural Exposures to Phytoestrogens. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2014, 101, 114-124.	1.4	6
57	Biomonitoring Equivalents for interpretation of silver biomonitoring data in a risk assessment context. International Journal of Hygiene and Environmental Health, 2016, 219, 521-526.	2.1	5
58	Extrapolation of plasma clearance to understand species differences in toxicokinetics of bisphenol A. Xenobiotica, 2018, 48, 891-897.	0.5	5
59	Derivation of Biomonitoring Equivalents for aluminium for the interpretation of population-level biomonitoring data. Regulatory Toxicology and Pharmacology, 2021, 122, 104913.	1.3	3
60	Risk assessment for children exposed to decabromodiphenyl (oxide) ether (Deca) in the United States. Integrated Environmental Assessment and Management, 2006, 2, 2-12.	1.6	3
61	Deriving Biomonitoring Equivalents for selected E- and P-series glycol ethers for public health risk assessment. International Journal of Hygiene and Environmental Health, 2016, 219, 88-100.	2.1	2
62	Derivation of biomonitoring equivalents (BE values) for bismuth. Regulatory Toxicology and Pharmacology, 2020, 114, 104672.	1.3	2
63	Risk assessment and Biomonitoring Equivalent for 2-ethylhexyl-2,3,4,5 tetrabromobenzoate (TBB) and tetrabromobenzoic acid (TBBA). Regulatory Toxicology and Pharmacology, 2017, 89, 186-192.	1.3	1